Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing

Taihang Shao^1*, Mingye Zhao^1*, Leyi Liang¹, Wenxi Tang^1,2#

1 Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China, 211198
2 Department of Public Affairs Management, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China, 211198

*These authors contributed equally to this work;
#Corresponding authors

PS: Codes in this repository are used to reproduce this analysis.
Original data are also provided in this repository.

Any questions or technical consulting:
Email: [email protected]